Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (BHC)
NYSE:BHC
RESEARCH TOOLSreports
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.93Last Year’s EPS
1.06Same Quarter Last Year
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: -16.04%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
Bausch Health demonstrated strong financial performance with growth in revenue and EBITDA, successful refinancing efforts, and legal victories. However, the company faces challenges with increased interest expenses and potential impacts from tariffs and trade measures.Company Guidance
In the first quarter of 2025, Bausch Health, excluding Bausch + Lomb, reported a year-over-year revenue growth of 6% and a 14% increase in adjusted EBITDA. The company successfully completed a $7.9 billion refinancing to extend its debt maturities, retiring approximately $6.9 billion of maturities from 2025 to 2028. The refinancing increased the cost of capital by 100 basis points. Bausch Health maintained its full-year 2025 guidance for revenue and adjusted EBITDA but updated its guidance for adjusted operating cash flow to account for higher interest expenses due to the refinancing. Segment-wise, Solta Medical achieved a 33% organic revenue growth, driven by strong performances in South Korea and China, while the International segment grew 5% organically. Meanwhile, the Salix segment saw a 6% organic growth, with Xifaxan achieving 8% growth. The company is exploring various strategic options, including share buybacks, to unlock shareholder value, as they believe the stock is undervalued.Revenue and EBITDA Growth
Bausch Health delivered year-over-year revenue and adjusted EBITDA growth of 6% and 14% respectively, excluding Bausch + Lomb.
Successful Refinancing
Completed a $7.9 billion refinancing effort to extend near and medium-term maturities, retiring approximately $6.9 billion of maturities ranging from 2025 into 2028.
Legal Victory
Received a favorable ruling from the D.C. District Court in the Norwich Case against the FDA.
Solta Medical Segment Growth
Solta Medical delivered 33% organic revenue growth, with notable performances in South Korea (136% growth) and China (30% growth).
International Segment Resilience
International segments achieved organic revenue growth across Canada, Latin America, and EMEA, with Canada's promoted product portfolio growing by 18%.
BHC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BHC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | $5.30 | $5.30 | 0.00% |
Feb 19, 2025 | $6.51 | $7.18 | +10.29% |
Oct 30, 2024 | $8.17 | $9.20 | +12.61% |
Jul 31, 2024 | $5.96 | $6.03 | +1.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bausch Health Companies (BHC) report earnings?
Bausch Health Companies (BHC) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Bausch Health Companies (BHC) earnings time?
Bausch Health Companies (BHC) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BHC EPS forecast?
BHC EPS forecast for the fiscal quarter 2025 (Q2) is 0.93.